Based on an analysis of withdrawn drugs that gained approval through the FDA's fast-track program, Columbia researchers argue that such programs have positively contributed to drug development.
Bristol-Myers Squibb Company today announced that Columbia University Medical Center and Peter MacCallum Cancer Centre have joined the International Immuno-Oncology Network.
In her JAMA editorial, Columbia oncologist Dawn Hershman says clinical trials show cooling caps reduce hair loss in some women undergoing chemotherapy.
Collaboration will investigate a system biology approach to identifying treatment options for patients with advanced gastrointestinal stromal tumors (GIST).
Columbia University researchers have created a user-friendly program that rapidly predicts which genes are implicated in an individual’s cancer and recommends treatments.
In a phase 1 study, eight out of 12 patients with relapsed and/or refractory blood cancers responded to a combination of two common chemotherapy drugs.
Dr. Drake studies the body’s immunological response to radiation therapy and how immunotherapy and radiation therapy can be used in concert to treat cancer.
Adding a new drug called olaratumab to traditional chemotherapy increased survival in sarcoma patients, researchers at Columbia University Medical Center have found.